据麦姆斯咨询介绍，双特异性抗体（BsAb）在肿瘤学领域正经历快速增长，已取得重大临床进展。最新数据显示，有85%以上的临床试验BsAb用于癌症治疗，目前约有600种BsAb正在进行临床试验。迄今，已有11种BsAb获得了用于癌症治疗的监管批准，其中1 ...

Much of this understanding has made it possible to enter an era of bispecific clinical development with two such molecules (catumaxomab and blinatumomab) having been approved for clinical use in ...

Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically for High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC): Interim Analysis of a Phase I Study ESMO 2024: STAR-EV: ...

Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not ...

Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

Human antibodies take center stage, as they pile up in the list of approved biologics in 2009. Cormac Sheridan reports. Last year was a vintage year for the bio-pharmaceutical industry in two ...